BioStock: Chordate makes progress in Italy, China and Saudi Arabia

Chordate Medical’s year-end report for 2022 does not show very large sales for either the full year nor the fourth quarter. However, the company’s latest press releases presents progress on several markets. In Italy, 11 clinics are up and running with the K.O.S treatment and the goal is to reach more clinics in 2023. In China, the joint venture company Changyong Medical Technology has submitted an application for product registration for the rhinitis treatment. In addition, Chordate Medical is now able to resume customer orders in Saudi Arabia. BioStock contacted CEO Anders Weilandt to get to know more.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/03/chordate-makes-progress-in-italy-china-and-saudi-arabia/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se